Key result
Iminostilbene improves post-MI cardiac function and reduces fibrosis by inhibiting fibroblast activation via Gal3/TGF-β1/Smad3.
Why the study?
Does iminostilbene alleviate myocardial fibrosis and improve cardiac function after myocardial infarction?
Does iminostilbene alleviate myocardial fibrosis and improve cardiac function after myocardial infarction?
Iminostilbene shows potential as a therapeutic agent to alleviate myocardial fibrosis and improve cardiac function post-myocardial infarction via the Gal3/TGF-β1/Smad3 pathway.
Answers are grounded in this paper and cite their sources.
Supports Gal3 inhibition for post-MI fibrosis in animals; hypothesis-generating, no clinical translation yet.
: Iminostilbene can be used to inhibit CFs activation through the Gal3/TGF-β1/Smad3 pathway, improve cardiac function, and alleviate cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question. Iminostilbene improves cardiac function and alleviates myocardial fibrosis after myocardial infarction by inhibiting cardiac fibroblast activation through the Gal3/TGF-β1/Smad3 pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: